the fy17 defense appropriations act provides $12 million (m) to the department of defense reconstructive transplant research program (rtrp) to support research of exceptional scientific merit that has the potential to make a significant impact on improving the function, wellness, and overall quality of life for injured military service members and veterans, their caregivers and family members, and the american public.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy17 rtrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

focus areas:  the fy17 rtrp encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (vca) in the following focus areas:

1. immune system regulation as specifically applied to vca
2. psychosocial considerations and challenges associated with vca
3. develop ex vivo vca tissue preservation techniques or technologies to extend the time between procurement and transplantation (goal: 24 hours)
4. develop pre-habilitation or rehabilitation strategies that improve reconstructive transplant functional outcomes
5. develop standardized quantitative functional outcome measures for vca, especially for face transplant
6. graft clinical monitoring – acute and chronic, as applied to vca 

concept award – letter of intent due november 15

• investigators at or above the level of postdoctoral fellow (or equivalent)
• pre-application (letter of intent) is required.
• supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
• preliminary data are not allowed.
• reviewers at both tiers of review will be blinded to the identity of the principal investigator (pi), collaborators, and their organizations.
• applications must address at least one of the fy17 rtrp focus areas.
• maximum funding of $200,000 for total costs (direct plus indirect costs)
• maximum period of performance is 18 months

investigator-initiated research award – preproposal due september 20

• independent investigators at all academic levels (or equivalent)
• preproposal is required; full application submission is by invitation only.
• supports studies with potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
• preliminary or published data required.
• multiple pi option supports synergistic partnerships among two to four  investigators collaborating on a single application; multi-institutional collaborations are encouraged
• applications must address at least one of the fy17 rtrp focus areas.
• individual pis:
• maximum funding of $1 million (m) for total costs
• maximum period of performance is 3 years
• multiple pi option:
• maximum funding of $1.5m for total costs
• maximum period of performance is 3 years

technology development award – preproposal due september 20

• independent investigators at all academic levels (or equivalent)
• preproposal is required; full application submission is by invitation only.
• supports research critical for the translation of promising preclinical findings into products focused on reconstructive transplantation.
• proof of concept must be established.
• transition plan is required.
• applications must address at least one of the following fy17 rtrp focus areas:
• develop ex vivo vca tissue preservation techniques or technologies to extend the time between procurement and transplantation (goal: 24 hours)
• graft clinical monitoring – acute and chronic, as applied to vca
• maximum funding of $1m for total costs
• maximum period of performance is 3 years

qualitative research award – preproposal due september 20

• independent investigators at all academic levels (or equivalent)
• preproposal is required; full application submission is by invitation only.
• supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering or have already received reconstructive transplant surgery.
• demonstrated qualitative research experience within the research team is required.
• theoretical perspective of qualitative research must be identified.
• rigorous and appropriate data collection and data analyses methods are important components.
• multiple pi option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
• applications must address the following fy17 rtrp focus area:
• psychosocial considerations and challenges associated with vca
• individual pis:
• maximum funding of $1m for total costs
• maximum period of performance is 3 years
• multiple pi option:
• maximum funding of $1.5m for total costs
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the rtrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

the objective of the idea to innovation (i2i) grants  is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established canadian company. the i2i grants provide funding to college and university faculty members to support research and development projects with recognized technology transfer potential. this is achieved through defined phases by providing crucial assistance in the early stages of technology validation and market connection.

please contact the economic development and innovation office as soon as possible if you are planning a submission to this program,

defence research and development canada (drdc), is looking for an epidemiologist or a health care practitioner in a community health setting to generate and analyze a comprehensive list of drdc’s records and data, to assist them in creating a strategy to monitor and reduce the impact of musculoskeletal injuries (msk’s) in the canadian armed forces population.

the canadian institute for military and veteran health research (cimvhr) has entered into partnership with the government of canada to procure research and development services related to the mental, social and physical wellbeing of active military members, veterans and their families.  cimvhr is seeking notices of interest from qualified researchers or a research team to produce this work.

the successful candidate(s) will have the following minimum qualifications:

•        one or more senior investigators with an md or a phd in epidemiology or health care practitioner in community health / public health;
•        post-graduate training in injury prevention epidemiology preferred;
•        demonstrated experience in research design and analysis appropriate to the scope of work;
•        experience or knowledge of the prevention of injuries would be an asset;
•        knowledge of the military injury system would be an asset;
•        a faculty appointment at one of cimvhr’s partner universities (https://cimvhr.ca/university-partners);
•        be able to meet project deliverables within stated timelines; 
•        please see the statement of work (https://cimvhr.ca/cimvhr-opportunities) for more details.

the competition consists of a two-stage application process, and each project requires a co-lead from an ontario and quebec institution. the application form, as well as the competition guide with complete program and submission details, is available at: http://www.omafra.gov.on.ca/english/research/onqc_research/index.html

the innovate call for proposals (the call) seeks applications from eligible organizations, companies and institutions (i) to pilot a non-traditional finance (ntf) product/service focused on rapid testing and learning or (ii) to document through a case study an ongoing or completed initiative related to ntf. the initiatives should demonstrate the potential and/or ability of products, services, or delivery channels that can catalyze and/or foster the adoption of agricultural innovations by women and men smallholder farmers in east africa, south america (the andes) and south asia.

innovate aims to learn from the experiences of the grant recipients; to test and document which products, services or delivery channels have potential to catalyze agricultural innovation by smallholder farmers. therefore, a key focus of the call is learning. the call also has a focus on gender, in which applicants shall clearly differentiate between women and men’s priorities and needs, treating them as distinct market segments in the proposal and research process.

successful proposals will be awarded up to cad $200,000 (pilot award) or up to cad $50,000 (case study award).

eligibility criteria

• minimum organizational requirements:
  • legally registered entities with audited financial statements for the last two years and proof of legal registration for a commercial entity/ngo, or proof of legal registration for a research institute and current financial policy and procedures
  • minimum three years' experience
• applicants shall propose initiatives for implementation in the target regions/countries:
  • east africa (burundi, kenya, malawi, rwanda, tanzania, uganda)
  • south america (bolivia, colombia, ecuador, paraguay, peru)
  • south asia (bangladesh, india, nepal, pakistan, sri lanka)
• applicants shall apply only for one type of grant and clearly identify/demonstrate a matching contribution.

what kind of support does the postdoctoral fellowships program provide?

the postdoctoral fellowships (pdf) program provides support to a core of the most promising researchers at a pivotal time in their careers. the fellowships are also intended to secure a supply of highly qualified canadians with leading edge scientific and research skills for canadian industry, government and universities.

are you eligible for a pdf?

to be considered eligible for support, as of the deadline date of the year in which you apply, you must:

• be a canadian citizen or a permanent resident of canada;
• hold or expect to hold a doctorate in one of the fields of research that nserc supports.

in addition:

• you must have completed all requirements of your first doctoral degree no more than two years before the deadline date of the year in which you apply.
• if you have acquired at least six months of full-time relevant employment in industry or government (experience in a university or its affiliated hospitals, research institutions and other laboratories will not be considered) after you received your doctorate, nserc will extend this eligibility period to three years.
• if, within two years following the date of completion of your phd, you withdraw from the workforce and from active research for parental leave or to raise a child for at least one year, nserc will extend this eligibility period to six years.

fy17 bcrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

applications submitted to the fy17 bcrp must address one or more of the following overarching challenges:

·         prevent breast cancer (primary prevention)

·         identify determinants of breast cancer initiation, risk, or susceptibility

·         distinguish deadly from non-deadly breast cancers

·         conquer the problems of overdiagnosis and overtreatment

·         identify what drives breast cancer growth; determine how to stop it

·         identify why some breast cancers become metastatic

·         determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to prevent recurrence

·         revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

·         eliminate the mortality associated with metastatic breast cancer

breakthrough award – letter of intent for levels 1 & 2, november 21

·         investigators at all academic levels (or equivalent)

·         senior postdoctoral fellows who do not meet the eligibility requirements of the breakthrough fellowship award are encouraged to apply under funding levels 1 and 2

·         each investigator may submit only one funding level 1 application and one funding level 2 application as a pi or initiating pi,
supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·         partnering pi option allows two principal investigators (pis), termed initiating and partnering pis, to collaborate on a single application.

·         it is the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·         there are no limitations on the number of applications for which an investigator may be named as a partnering pi.  however, applicants are discouraged from submitting as a partnering pi on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·         additional funds are available for applications submitted under the partnering pi option.

·         clinical trials are not allowed.

·         submission of a letter of intent is required prior to full application submission.

funding level 1:

·         maximum funding of $375,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

funding level 1 – partnering pi option:

·         maximum funding of $600,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

funding level 2:

·         maximum funding of $750,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

funding level 2 – partnering pi option:

·         maximum funding of $1 million (m) for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

breakthrough award –preproposal for levels 3 & 4 september 29

·         independent investigators at all academic levels (or equivalent) are eligible.

·         each investigator may submit only one funding level 3 pre-application and one funding level 4 pre-application as a pi or initiating pi

·         supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         potential impact of the research may be near-term or ling-term, but it must be significant and go beyond an incremental advancement.

·         partnering pi option allows two pis, termed initiating and partnering pis, to collaborate on a single application.

·         is it the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

·         there are no limitations on the number of applications for which an investigator may be named as a partnering pi.  however, applicants are discouraged from submitting as a partnering pi on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·         pi’s must include two or more breast cancer advocates on their research team.

·         submission of a proposal is required: application submission is by invitation only.

funding level 3:

·         maximum funding of $2.5m in direct costs (plus indirect costs)

·         maximum period of performance is 4 years

funding level 3 – partnering pi option:

·         maximum funding of $4m for direct costs (plus indirect costs)

·         maximum period of performance is 4 years

funding level 4 and funding level 4 – partnering pi option:

·         maximum funding of $10m for direct costs (plus indirect costs)

maximum period of performance is 4 years

breakthrough fellowship award – letter of intent due november 21

as of the application submission deadline, all eligible pis must have:

·         successfully completed the requirements for a doctoral or medical degree, and

·         been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

·         a total of less than 4 years experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

mentor

must have breast cancer research experience, including current funding and recent publications

·         supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of promising research that has the potential to lead to or make breakthroughs in breast cancer.

·         potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·         individualized researcher development plan and mentorship should prepare the pi for an independent career at the forefront of breast cancer research or patient care.

·         the pi is not required to have previous experience in breast cancer research.

·         preliminary data are allowed, but not required.

·         maximum funding of $300,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

era of hope scholar award – letter of intent due november 21

must be an independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

·         supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.

·         pis should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

·         pis must exhibit strong potential for leadership in breast cancer.

·         experience in breast cancer is not required: however, the application must focus on breast cancer, and the pi must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.

·         pis must include breast cancer advocates on their research team.

·         submission of a letter of intent is required prior to full application submission.

• maximum funding of $2.5m for direct costs (plus indirect costs)

·         maximum period of performance is 4 years

innovator award – pre-application due september 29

must be an associate professor or above (or equivalent).

·         supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.

·         provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

·         experience in breast cancer research is not required: however, the application must focus on breast cancer, and the pi must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer.

·         pis must include breast cancer advocates on their research team.

·         preproposal is required; application submission is by invitation only.

• maximum funding of $5m for direct costs (plus indirect costs).

·         maximum period of performance is 4 years.

distinguished investigator award – pre-application due september 29

pis must be at or above the level of assistant professor (or equivalent) and more than 6 years beyond the pi’s last training position as of the application submission deadline

·         supports established visionary leaders from any filed to pursue innovative ideas that could accelerate progress toward ending breast cancer.

·         the pi must propose research that is a fundamental shift from his/her track record of research.

·         does not support continuation of or incremental change from the pi’s published line of research.

·         if the pi is an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a fundamental shift in his/her research and must include at least one collaborator with breast cancer expertise.

·         high-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

·         pis must include two or more breast cancer advocates on their research team.

·         submission of a preproposal is required; application submission is by invitation only.

• maximum funding of $3m for direct costs (plus indirect costs)

·         maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the bcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

asthma canada/allergen graduate student research awards

asthma canada and allergen have partnered to co-fund graduate student research awards related to early-onset and late-onset asthma.

asthma canada is a national organization that provides evidence-based, age-appropriate asthma information, education, management tools and support programs for canadians with asthma. asthma canada also supports strategic research to improve the quality of life of people living with asthma, and ultimately find a cure.

these graduate training awards will create value-added opportunities for the training, education, and professional development of graduate 世界杯2022赛程表淘汰赛 who will strengthen canada’s knowledge base and scope for innovation. these awards will build capacity amongst young canadian researchers to ensure continued improvement of treatments and ongoing process working towards finding a cure for asthma.

2017 competition deadline: september 30, 2017

objectives of the innovation in apprenticeship stream

the innovation in apprenticeship stream has the following specific objectives:

• support innovation and enhanced partnerships to address long-standing and complex challenges that limit apprenticeship outcomes; and
• improve the participation and success of key groups in trades training and careers (e.g., women, indigenous people, newcomers, persons with disabilities).

expected results

through the development, testing, evaluation and promotion of innovative approaches, or the expansion/replication, and evaluation of best practices, project proposals must contribute to the following utip program expected results (outcomes):

• individuals have the improved skills to succeed in the trades;
• individuals (including women and indigenous people) progress through apprenticeship training;
• individuals experience improved labour market outcomes in the red seal trades; and
• enhanced engagement of apprenticeship stakeholders and partners.

please note that organizations can only one application under this stream.  if you are interested in applying to this opportunity, please notify the office of research services (ahacquo1@lakeheadu.ca) no later than august 10, 2017.